| Date |
Subject |
Media |
| 2025-07-13 |
SG Biomedical Advances Innovative Plasma Medical Technology, Setting New Milestones in Healthcare Industry
|
SG Biomedical specializes in innovative plasma medical technology, pioneering the use of plasma treatment for chronic wounds in surgical care. With over 18 years of clinical evidence from hospitals in Germany, the UK, and the European Union, its efficacy has been validated by more than 82 professional medical journals worldwide. The technology is applicable to various types of wound care, including acute and chronic large wounds, diabetic foot ulcers, surgical wound infections, and burn infections. |
| 2025-07-06 |
TBMC to Build Taiwan’s First GMP Facility for Nucleic Acid Drugs, Targeting Launch in First Half of 2026
|
Taiwan Bio-Manufacturing Corporation (TBMC) held a groundbreaking ceremony on the 26th for its new GMP facility in Zhubei, marking the official launch of the nation’s first GMP-compliant manufacturing base for mRNA nucleic acid drugs and vaccines. The facility is slated for operation in the first half of 2026. Chairman Patrick Y. Yang stated that this represents a key milestone in TBMC’s journey toward becoming a world-class pharmaceutical CDMO. |
| 2025-07-06 |
Andros Pharmaceuticals Reports Positive Phase II Results for APC201, Initiates Global Licensing
|
On June 26, Andros Pharmaceuticals announced on behalf of its subsidiary that the Phase I/IIa clinical trial for its novel drug APC201—designed to treat localized knee osteoarthritis pain—has yielded positive Phase II results in Australia. Both primary and secondary efficacy endpoints were met, indicating good overall safety and tolerability, with preliminary data showing a trend toward pain reduction in study participants. |
| 2025-07-06 |
APRINOIA Therapeutics Targets Early Diagnosis Market for Dementia
|
APRINOIA Therapeutics is advancing into the early diagnosis market for dementia. On June 25, company founder Ming-Kuei Jang stated that the presence of Tau protein is highly correlated with neurodegeneration and disease progression, making it a gold standard for early diagnosis. APRINOIA’s lead imaging agent, APN-1607, enables visualization of Tau protein deposition in the brain and is currently undergoing regulatory review in Taiwan, China, the United States, and Japan. Taiwan may become the first market to approve the product. |
| 2025-07-06 |
Sunfun Info Pursues Triple-Growth Strategy in 2025; Subsidiary Daiken Biomedical Gains Listing Approval
|
Sunfun Info held its annual shareholders’ meeting on June 26, chaired by Chairman Chia-Ming Chang, where it approved a fourth-quarter 2024 dividend distribution of NT$0.2036 per share in cash. To strengthen working capital and support future investments in new ventures—particularly in AI and the beauty & housing sectors—the company plans to issue both cash and stock dividends in parallel. Meanwhile, on June 25, its subsidiary Daiken Biomedical received formal approval for its initial public offering from the Taiwan Stock Exchange Board of Directors. |
| 2025-07-06 |
Orient EuroPharma Introduces Cancer-Fighting Photoimmunotherapy in Collaboration with Japan’s Rakuten Medical
|
A new breakthrough in cancer treatment is on the horizon. Orient EuroPharma (OEP) Group has announced that it has secured the commercial rights to Rakuten Medical’s photoimmunotherapy platform in Taiwan, Singapore, Malaysia, and the Philippines. This marks Rakuten Medical’s first licensing agreement with a Taiwanese pharmaceutical company. The therapy is currently undergoing Phase III clinical trials in Taiwan, with the goal of obtaining local regulatory approval next year. Rakuten Medical also plans to consolidate clinical data from Taiwan, the U.S., and Japan to pursue FDA approval in the U.S., further expanding the reach of this innovative treatment. |
| 2025-07-06 |
Sofiva Genomics Advances Precision Medicine with Strategic Focus on Cancer, Dementia, and Reproductive Health
|
At its institutional investor conference on the 25th, Sofiva Genomics outlined its three major strategic priorities, with Chairman Yi-Ning Su personally presenting the company’s vision: integration into Taiwan’s NGS (next-generation sequencing) national health insurance coverage, active expansion into cancer and Alzheimer’s genetic screening markets, and growth in PGT-A applications in assisted reproduction. As the scope of its products and services continues to expand, Sofiva Genomics is poised for a new wave of growth. |
| 2025-07-06 |
EpiSonica Secures Medical Device Approvals in Indonesia and Thailand, Accelerates Southeast Asia Expansion
|
EpiSonica’s flagship product, the ArcBlate MRgHIFU—an image-guided focused ultrasound surgical system—has received market clearance from the Thai Food and Drug Administration, following its approval by Indonesia’s Ministry of Health in late August last year. The device is approved for the treatment of adenomyosis and uterine fibroids. |
| 2025-07-02 |
3D Global Biotech to Launch IPO Application in Q3, Eyes Growth with Pediatric Myopia Control Products
|
3D Global Biotech is set to initiate its IPO process, with plans to submit an application for listing on the Taiwan Innovation Board or over-the-counter (OTC) market as early as the third quarter. Targeting opportunities in the ocular health market, the company leverages its proprietary nano-surface functional crosslinking technology to enhance the water content and moisture retention of contact lenses. Following its initial shipments of adult contact lenses to clients in China at the end of last year, 3D Global Biotech will also introduce orthokeratology lenses for pediatric myopia control, with shipments to China expected in the second half of the year. |
| 2025-07-02 |
Pharmosa Biopharm Announces EU Orphan Drug Designation for Investigational Drug L608
|
Pharmosa Biopharm announced on June 24 that it has received official written notification from the European Commission, confirming that its investigational drug L608 has been granted Orphan Drug Designation (ODD) by the European Medicines Agency (EMA) for the treatment of systemic scleroderma (SSc). |
